[Immunoactive effects of various mistletoe lectin-1 dosages in mammary carcinoma patients].
Cellular aspects of the immunomodulating activity of a proprietary mistletoe extract (Eurixor) standardized for mistletoe lectin-1 (ML-1) were investigated in patients suffering from mammary carcinoma (n = 20). Regular subcutaneous injections of the different dosages (0.5 and 1.0 ng ML-1/kg body weight, twice a week, for 5 weeks) yielded statistically significant increases of defined peripheral blood lymphocyte subsets (helper T-cells, natural killer (NK)-cells) which are generally believed to be involved in antitumor activity. Moreover, administration of either ML-1 concentration resulted in enhanced expression of activation markers such as interleukin-2 receptors and HLA/DR-antigens on peripheral blood T-lymphocytes. This study suggests that regular subcutaneous administration of both ML-1 concentrations (0.5 and 1.0 ng/kg body weight) can efficiently stimulate the cellular immune system of cancer patients.
Beuth
J
J
Institut für Medizinische Mikrobiologie und Hygiene, Universität zu Köln.
Stoffel
B
B
Ko
H L
HL
Buss
G
G
Tunggal
L
L
Pulverer
G
G
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000276:immunology*; D005260:Female; D006684:HLA-DR Antigens; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D037102:Lectins / Q000494:pharmacology; D028321:Plant Preparations; D010940:Plant Proteins; D015375:Receptors, Interleukin-2 / Q000096:biosynthesis; D054790:Ribosome Inactivating Proteins, Type 2; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D006377:T-Lymphocytes, Helper-Inducer / Q000187:drug effects / Q000276:immunology; D014118:Toxins, Biological / Q000494:pharmacology*
D000276:Adjuvants, Immunologic; D006684:HLA-DR Antigens; D037102:Lectins; D028321:Plant Preparations; D010940:Plant Proteins; D015375:Receptors, Interleukin-2; D054790:Ribosome Inactivating Proteins, Type 2; D014118:Toxins, Biological; C009674:ribosome inactivating protein, Viscum
Immunaktive Wirkung verschiedener Mistellektin-1-Dosierungen in Mammakarzinom-Patientinnen.